ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,745.37
0.40%
US Tech 100
19,551.60
-0.14%
Dow Jones
42,175.11
0.62%
Brent Oil
71.045
0.13%
Bitcoin
65,726.00
0.83%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cellectis SA (CLLS)

  7. Cellectis SA (CLLS) News

CLLS

Cellectis (CLLS)

Cellectis SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CLLS
DateTimeSourceHeadlineSymbolCompany
09/11/20244:30PMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:CLLSCellectis SA
09/03/20244:30PMGlobeNewswire Inc.Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving SafetyNASDAQ:CLLSCellectis SA
08/26/20244:31PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
08/26/20244:30PMGlobeNewswire Inc.Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid TumorsNASDAQ:CLLSCellectis SA
08/07/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
08/07/20242:00AMGlobeNewswire Inc.Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical OfficerNASDAQ:CLLSCellectis SA
08/06/20244:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
08/06/20244:30PMGlobeNewswire Inc.Cellectis Provides Financial Results for the Second Quarter 2024NASDAQ:CLLSCellectis SA
08/01/20244:30PMGlobeNewswire Inc.FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL TreatmentNASDAQ:CLLSCellectis SA
07/25/20244:30PMGlobeNewswire Inc.FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) TreatmentNASDAQ:CLLSCellectis SA
06/28/20244:30PMGlobeNewswire Inc.Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024NASDAQ:CLLSCellectis SA
06/20/20244:30PMGlobeNewswire Inc.Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base EditingNASDAQ:CLLSCellectis SA
06/12/20244:35PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
06/12/20244:30PMGlobeNewswire Inc.Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature CommunicationsNASDAQ:CLLSCellectis SA
06/04/20244:41PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
06/04/20244:30PMGlobeNewswire Inc.Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaNASDAQ:CLLSCellectis SA
05/29/20244:35PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
05/29/20244:30PMGlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024NASDAQ:CLLSCellectis SA
05/28/20244:30PMGlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024NASDAQ:CLLSCellectis SA
05/28/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
05/27/20244:30PMGlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024NASDAQ:CLLSCellectis SA
05/24/20244:06PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
05/06/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
05/06/20242:00AMGlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:CLLSCellectis SA
05/02/20244:30PMGlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerNASDAQ:CLLSCellectis SA
04/29/20244:46PMGlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:CLLSCellectis SA
04/22/20244:30PMGlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsNASDAQ:CLLSCellectis SA
04/10/20244:30PMGlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsNASDAQ:CLLSCellectis SA
04/08/20244:30PMGlobeNewswire Inc.Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual MeetingNASDAQ:CLLSCellectis SA
01/16/20244:45PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CLLSCellectis SA
 Showing the most relevant articles for your search:NASDAQ:CLLS

Your Recent History

AQSE
ALBA.GB
Alba Min
BIT
P1S8O5
BNP Paribas Issuance
BIT
S30627
Societe Generale Effekten
BIT
P17XS1
BNP Paribas Issuance
BIT
S5LMDB
Societe Generale Effekten
BIT
UB3RQ4
Unicredit Bank
BIT
P16JN3
BNP Paribas Issuance
BIT
UR9ZMK
UniCredit Bank
BIT
P1RHP8
BNP Paribas Issuance
BIT
P34274
Bnp Paribas Issuance
BIT
P1P5F2
BNP Paribas Issuance
BIT
UB6DGE
Unicredit Bank
BIT
P1VUE7
NLBNPIT1VUE7 20991231 50...
BIT
UC92AG
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved